News | August 09, 2022
Margin disappointment continues for Lupin in Q1FY23 : Prabhudas Lilladher
Margins under pressure - Price erosion, shelf stock adjustments and inventory pare down in US biz impacted margins.
Margins under pressure - Price erosion, shelf stock adjustments and inventory pare down in US biz impacted margins.
Profit after Tax stood at Rs. 105 crore as compared to Rs. 119 crore on account of higher treasury income in Q1 FY22, non-cash ESOP cost, depreciation on account of acquired brands and finance costs in Q1 FY23
Based on DESTINY-Breast04 results which showed Daiichi Sankyo and AstraZeneca’s ENHERTU reduced risk of disease progression or death by 50% and increased overall survival by more than six months versus chemotherapy
Patritumab deruxtecan is a specifically designed potential first-in-class HER3 directed antibody drug conjugate (ADC) discovered and being developed by Daiichi Sankyo.
The 562,000 square feet facility has been recognized as the first and largest integrated insulin manufacturer in Malaysia by MBR
Profit after Tax (PAT) was up 18% for Q1 FY23 to reach Rs. 28.7 crore whereas EBITDA was up 52% to reach Rs. 57.7 crore
With this expansion, the Grand Island site provides redundant capacity to support global supply of media and further extends the site’s capabilities to produce the high-quality technology and materials needed for the development and commercial manufacturing of vaccines and biologic therapies
Despite the price increases for raw materials and logistics, EBITDA pre rose organically by 3.2% to € 1,782 million
Sandu Kumarvin is an Ayurvedic digestive and immunity booster for children and also offers several other benefits.
The safety profile of KEYTRUDA plus LENVIMA was consistent with previously reported data on the combination.
Subscribe To Our Newsletter & Stay Updated
